Analyst Ratings For Abeona Therapeutics Inc (NASDAQ:ABEO)
Today, HC Wainwright reiterated its Buy rating on Abeona Therapeutics Inc (NASDAQ:ABEO) with a price target of $30.00.
There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Abeona Therapeutics Inc (NASDAQ:ABEO) is Buy with a consensus target price of $26.8750 per share, a potential 310.31% upside.
Some recent analyst ratings include
- 2/21/2019-Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by HC Wainwright with a $30.00 price target
- 12/10/2018-Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by Mizuho with a $17.00 price target
- 12/6/2018-Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by Cantor Fitzgerald with a $36.00 price target
- 11/5/2018-Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by Maxim Group with a $26.00 price target
- 6/27/2018-Abeona Therapeutics Inc (NASDAQ:ABEO) has coverage initiated with a Buy rating and $26.00 price target
- 6/5/2018-Abeona Therapeutics Inc (NASDAQ:ABEO) has coverage initiated with a Buy rating and $29.00 price target
- On 9/20/2016 Todd Wider, Director, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00.
- On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00.
- On 1/26/2015 Mark J Ahn, Director, bought 25,000 with an average share price of $4.00 per share and the total transaction amounting to $100,000.00.
- On 12/24/2014 Steven H Rouhandeh, Director, bought 250,000 with an average share price of $4.00 per share and the total transaction amounting to $1,000,000.00.
About Abeona Therapeutics Inc (NASDAQ:ABEO)
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Recent Trading Activity for Abeona Therapeutics Inc (NASDAQ:ABEO)
Shares of Abeona Therapeutics Inc closed the previous trading session at 6,55 −0,13 1,95 % with 6.77 shares trading hands.
